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ABSTRACT
Alzheimer’s disease is the sixth leading cause 
of death in the United States. The leading 
hypothesis to explain the prevalence of the 
disease in the brain is the aggregation of 
Amyloid Beta peptides in the brain, which 
form senile plaques and suppress neuronal 
function. Selective estrogen receptor 
modulators (SERMs) have been found to 
provide protective effects against the 
neurotoxic effects of Amyloid Beta. This 
experiment was conducted in two distinct 
phases: the experimental phase and the 
literature review phase. The experimental 
phase sought to determine if Amyloid Beta 
was neurotoxic to SH-SY5Y neuroblastoma 
cells, and if STX—an SERM—was able to 
rescue cell viability after exposure to 
Amyloid Beta toxicity. During the literature 
review phase, potential pathways already 
described in the literature were identified, 
which might be able to account for how STX 
was able to rescue cell viability after 
exposure to Amyloid Beta toxicity. Amyloid 
Beta was found to have a significant toxic 
effect on cell viability when compared to a 
control assay of cells grown in DMSO. STX, 
however, was not found to have a significant 
rescue effect against Amyloid Beta toxicity. 
The literature review identified several 
pathways that were likely candidates for 
neuroprotection, including MAPK, ERK1, 
ERK2, and PI3K. The future direction of this 
experiment would be to determine if STX is 
as effective at providing neuroprotection 
against Amyloid Beta as previously 
suggested by similar experiments. the next 
stage of investigation would then be to inhibit 
different pathways that have been identified 
as possible pathways for neuroprotection. 
 
 
 
 
INTRODUCTION 
Alzheimer’s disease is a progressive brain 
disorder that causes impairment in memory 
and thinking skills (1). It was first described 
by Dr. Alois Alzheimer in 1906, who noted 
memory loss, paranoia, and psychological 
changes in his patient. Today, Alzheimer’s 
disease is the sixth leading cause of death in 
the United States (2). The factors that lead to 
Alzheimer’s disease are still unknown, 
though there are many hypotheses which 
seek to explain the etiology of cognitive 
impairments associated with the disorder. 
One of the leading explanations is the 
Amyloid Cascade hypothesis, proposed by 
J.A. Hardy and G.A. Higgins in 1992. 
Amyloid precursor protein (APP) is 
expressed by neuronal cells and extra-
neuronal tissues. Hardy and Higgins argue 
that the proteolytic cleavage of the membrane 
glycoprotein amyloid precursor protein into 
neurotoxic amyloid beta-peptide (Amyloid 𝛽) 
fragments was the cause of the cellular death 
process in the central nervous system (3). 
In the brain, APP is expressed in three 
isoforms: APP695, APP751, and APP770. 
APP695 is the most abundant isoform in 
neurons and is expressed at relatively high 
levels (4). As mentioned previously, APP is a 
membrane-bound glycoprotein. It is 
processed by membrane bound aspartic 
proteinases: 𝛼 and 𝛽 secretases. Each of the 
products generated by these proteinases is 
processed by 𝛾  secretase and the fragments 
are secreted into the cytoplasm. When the 
Amyloid  𝛽  domain is processed by 𝛼 
secretase, it is cleaved within the Amyloid 𝛽 
domain, between residues Lys16 and Leu17; 
this is referred to as the non-amyloidogenic 
pathway, as it inhibits the generation of intact 
Amyloid  𝛽  peptides. When processed by 𝛽 
secretase, it is cleaved at Asp1, which is 
referred to as the amyloidogenic pathway, as 
it forms intact Amyloid  𝛽  peptides (40-42 
amino acids long) that are released into the 
cytosol. These peptides will frequently 
aggregate in the brain and cause the 
development of senile plaques (5).  
Research into the function of APP secretases, 
specifically 𝛾 secretase, has been of interest 
to many investigators. By understanding this 
mechanism, it is though that we could stop 
the production and release of Amyloid  𝛽 
peptide, which would prevent plaque 
formation all together. Unfortunately, 𝛾 
secretase plays a critical role in the cleavage 
of other membrane proteins, such as the 
Notch1 receptor. Because of this, research 
into alternative methods of neuroprotection 
from Amyloid 𝛽 peptide is necessary (6).  
Estrogens have been shown to have 
neuroprotective effects against brain 
ischemia, as well as reduce memory 
impairment after an ischemic event (7). This 
makes estrogen a compelling compound of 
study for other conditions that cause 
cognitive impairment (7,8). There are 
significant risks, however, associated with 
17-𝛽 estradiol (E2) treatments; possible side 
effects include but are not limited to: 
cardiovascular disease, thrombosis, cerebral 
vascular accident, and hormone-sensitive 
cancers, among others. Selective estrogen 
receptor modulators (SERMs) are synthetic 
or natural compounds that provide the 
positive neuroprotective effects of estrogen 
without the negative side effects. STX is one 
example of a SERM. STX is able to bind to 
the G protein coupled estrogen receptor Gq-
mER in the plasma membrane instead of the 
nuclear estrogen receptors. This eliminates 
the negative transcriptional responses 
generated by E2 that lead to negative side 
effects (9). 
Building on the research developed by Gray 
et al. (9), my research will seek to understand 
the pathway that produces the protective 
effects of STX against Amyloid 𝛽  toxicity. 
My project will be undertaken through a 
mixed methodology of primary research and 
literature review. In the research phase of my 
experiment, I will establish that Amyloid 𝛽is 
toxic to SH-SY5Y neuroblastoma cells, 
which I will use as my cell culture assay of 
amyloid toxicity (9). My literature review 
will be focused on previous research 
conducted on the different signaling 
mechanisms of STX in the cell. This 
combined approach will address my research 
question: what is the pathway that provides 
STX its neuroprotective abilities against the 
harmful effects of Amyloid 𝛽? 
 
METHODOLOGY 
Experimental phase 
SH-SY5Y neuroblastoma cells were cultured 
in DMEM/F12 medium (GIBCO/Life 
Technologies) supplemented with 10% FBS 
and 1% penicillin-streptomycin (Sigma-
Aldrich). Cells were plated in 15,000 cells 
per well in 96 well plates to assess cell 
viability. Three days after plating, the cells 
were washed with phosphate-buffered saline 
(PBS; Sigma-Aldrich) and switched to 
serum-free DMEM/F12 medium containing 
1% N-2 growth supplement (GIBCO/Life 
Technologies) and 100nM STX (synthesized 
by our colleague Dr. Martin Kelly, Dept of 
Physiology and Pharmacology at Oregon 
Health and Science University). The next day, 
the cells were treated with 50 µM oligomeric 
A𝛽1-42 (prepared using the methods described 
by Stine et al (10)) and incubated at 37°C for 
72 hours. Cell viability was assessed 48 hours 
after incubation period using a Bio-Rad 
xMark microplate spectrophotometer.  
Literature review phase 
The effects of STX on G-protein coupled 
receptors (GPCRs) will be the focus of this 
study. Articles of focus will be peer reviewed 
journal articles that address the effects of 
STX on two different membrane estrogen 
receptors—G-protein coupled receptor 30 
(GPR30) and Gq-coupled membrane 
estrogen receptor (Gq-mER)—specifically 
with regards to the intracellular signaling 
cascades that are engaged, following their 
activation.   
 
RESULTS AND DISCUSSION 
Experimental phase 
In this experiment, Amyloid 𝛽 toxicity was 
evaluated after SH-SY5Y cells were treated 
with A𝛽1-42 and allowed to incubate for 72 
hours. When cells treated with A𝛽1-42 were 
compared to cells treated with DMSO, cell 
viability was found to be significantly 
decreased (Figure 1). From these results, it 
was determined that 50 µM oligomeric A𝛽1-
42 was found to be a sufficient concentration 
to reduce cell viability. 
To evaluate the protective effects of STX, 
cells were pre-treated with STX and then 
treated with A𝛽1-42. STX concentration was 
titrated to determine if there was a correlation 
between STX concentration and cellular 
rescue. When compared to cells treated with 
DMSO, there was no consistently observed 
statistically significant difference in cell 
viability between SH-SY5Y cells treated 
with A𝛽1-42 and STX and those without STX 
(Figure 2). During one trial, a statistically 
significant difference was observed between 
cells treated with A𝛽 1-42 without STX and 
those with STX, however, these results have 
not been able to be reproduced. This 
observation suggests that there may be 
confounding sources of error that might be 
impeding the experimental process. 
Possible explanations for the variation in the 
experimental results could be the preparation 
of A 𝛽 1-42 itself. The incubation period 
suggested for A𝛽1-42 is 4-7 days. During this 
time, A𝛽1-42 oligomerizes into a clear film, 
which will be resuspended in solution. 
However, because the film is clear, there is 
no good indication that the A 𝛽 1-42 has 
oligomerized or can bind to cells. It is also 
possible that the time window for aging is 
insufficient. A𝛽1-42 has been allowed to age 
for 4 days, but it is possible that increasing 
the time allotted for oligomerization would 
increase the concentration of A 𝛽 1-42 that 
actually forms.  
It is also possible that the difference between 
cellular concentration of each well has an 
allosteric effect on cellular viability. It is 
possible that the cellular network produced 
between larger concentrations of cells is 
better able to resist the toxic effects of A𝛽1-42. 
Decreasing the concentration of cells per well 
could potentially decrease the risk of a 
cellular network forming a resistance to A𝛽1-
42, but this is not a change that can be made 
in living organisms, and therefore might 
decrease the effectiveness of this model.  
We have not yet seen conclusive data that 
STX can reproducibly rescue SH-SY5Y cells 
from A𝛽1-42, however, we will continue to 
make changes to the experimental 
methodology to account for discrepancies in 
results gathered between trials.  
 
 
  
 
Figure 1. When cell 
viability after A𝛽1-42 
exposure was compared to 
cells exposed to 2.5% 
DMSO, cell viability 
decreased by a statistically 
significant amount 
(p=0.05). Fig1A shows a 
relationship between the 
concentration of A𝛽1-42 
and cell viability, while 
Fig1B shows that there 
was not demonstrate this 
correlation. Fig1C showed 
that 0.5uM A𝛽1-42 was 
sufficient to decrease cell 
viability a statistically 
significant amount. Y-axis 
of each graph has been 
scaled to be proportional 
to the cell viability of cells 
exposed to 0.5% DMSO.  
Concentration 
  
Figure 2. When cell viability of STX pre-
treated cells after A𝛽
1-42
 exposure was 
compared to cells exposed to 2.5% DMSO, 
there was no consistently significant 
difference between cells treated with STX and 
those without. Fig2A shows the results of an 
experiment performed in December 2018. No 
statistically significant difference was seen. 
Fig2B shows the results of an experiment 
performed in January 2019. A statistically 
significant difference was seen between cells 
treated with STX and those without (p=0.05). 
Fig2C shows the results of an experiment 
performed in April 2019. No statistically 
significant difference was seen.  
A 
B 
C 
Literature review  
Understanding the pathways involved in the 
neuroprotective effects of selective estrogen 
receptor modulators is extremely complex. 
Several pathways have been identified as 
likely candidates for neuroprotection, and 
they are not mutually exclusive. E2 is a useful 
reference compound, as it has very similar 
effects to SERMs in the body. Initiation of 
signaling pathways in hypothalamic arcuate 
neurons begins when E2 binds to the Gq-
mER and activates G𝛼q, a G-protein subunit. 
G 𝛼 q dissociates from the membrane and 
activates phospholipase C (PLC) and initiates 
the hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2). PLC then hydrolyzes 
PIP2 into diacylglycerol (DAG) and inositol 
1,4,5-triphosphate (IP3). DAG actives protein 
kinase C (PKC), which activates adenylate 
cyclase VII, which increases cAMP 
production and stimulates protein kinase A 
(PKA). PKA phosphorylation uncouples the 
inhibitory GABAB and µ-opioid receptor 
from activation of G-protein coupled, inward 
rectifying K+ (GIRK) channels. Activation of 
PKA also phosphorylates cAMP-responsive 
element binding protein and control gene 
expression through the CREB response 
element. IP3 activates Ca
2+ release from the 
endoplasmic reticulum that can activate 
calcium-dependent signaling. E2 also has 
been found to bind to the nuclear receptors 
and activate estrogen response element-
dependent transcription (11, 12).  
This latter finding highlights the important 
difference between E2 and SERMs: SERMs 
do not bind to nuclear receptors. This has 
been demonstrated in multiple studies. 
Indeed, it has been shown that the relative 
binding affinity of SERMs was reduced by 
about 1 million-fold when compared to E2. In 
addition to this, STX has been shown to 
activate the G𝛼q signaling pathway in mice 
that lack either ER𝛼, ER𝛽, or both nuclear 
receptors (11, 12). This suggests that there 
might be other differences between the 
behavior of STX and E2 within the cell, 
including their neuroprotective pathways.  
Compelling evidence has shown that STX 
binds to the Gq-mER rather than GPR30 (13, 
14). When STX was introduced into neurons 
that had the GPR30 genes silenced through 
an siRNA treatment, the molecule was still 
fully efficacious (8, 15). This suggests that 
GPR30 was not essential for the function of 
STX within the cell. Similar experiments, 
which block the release of G𝛼 from Gq-mER 
have been performed after cells were treated 
with E2 (13) and showed that blocking the 
release of the G-subunit is sufficient to block 
the effects of E2 in the cell. Reproduction of 
this experiment with STX would be the first 
step to understanding the method of action of 
STX in the cell. 
Inhibition of mitogen activated protein 
kinase/extracellular signal-regulated kinase 
(MAPK/ERK) pathways as well as 
phosphatidylionsitol 3-kinase (PI3K) 
pathways were shown to block the ability of 
STX to activate the steroidogenic factor 1 
(SF-1) in endometrial cells (15). Inhibition of 
ERK was also found to block the effects of 
STX in vivo (16).   STX was found to 
attenuate the GABAB response in cells, and 
the inhibition of GABAB by estrogen was 
found to be required for the activation of 
PKA intracellularly. In addition to this, 
PKC 𝛿  inhibitor was found to block the 
function of GABAB in cells treated with E2. 
PLC was not found to be an essential 
inhibitor of GABAB, but it does not rule out 
its possible significance in the STX pathway 
(13).  
It is possible that each of these pathways, 
MAPK/ERK, PI3K, PKA, PLC, or PKC 𝛿 
play a role in the effect of STX within the cell. 
As each of these pathways are non-genomic, 
they are the most likely candidates. It is also 
possible that this list is incomplete and that 
we do not have enough information about 
intracellular kinase pathways to yet answer 
this question. The next stage of research will 
be to treat neuroblastoma cells with A𝛽, STX, 
and each of these inhibitors and measure the 
cellular rescue response. Combinations of 
these inhibitors would also be interesting, to 
explore if more than one of these pathways is 
involved in the response initiation of STX. 
This is likely, given that this is the case for 
E2.  
Understanding this mechanism of cellular 
rescue will allow us to design more effective 
treatments for Amyloid 𝛽 toxicity and 
ischemic events. Wider applications to this 
research include but are not limited to: 
Alzheimer’s disease, Parkinson’s disease, 
stroke, and other cerebral vascular accidents.  
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